Succinobucol

Drug Profile

Succinobucol

Alternative Names: AGI-1067

Latest Information Update: 26 Jun 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AtheroGenics
  • Class Anti-ischaemics; Antihyperlipidaemics; Phenols
  • Mechanism of Action Antioxidants; Lipid peroxidation inhibitors; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 09 Jun 2009 Pharmacodynamics data from an in vitro study presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
  • 07 Oct 2008 AtheroGenics files for chapter 11 bankruptcy in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top